Clinical Trial Update: CP-481,715 Nickel Allergy Study. [Phase 1]

View source ↗

Summary

Pfizer's Phase 1 trial of CP-481,715 for allergic contact dermatitis (nickel allergy) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Contact Dermatitis

Drugs mentioned

• CP-481,715

Snippet

Sponsor: Pfizer | Conditions: Dermatitis, Allergic Contact | Phase 1 | Status: COMPLETED